Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease

At ARVO 2026, Ikarovec presented 4 posters showcasing its bicistronic platform that combines neuroprotection and complement modulation.

1

Ikarovec is developing dual-pathway gene therapies for retinal degenerative diseases using a bicistronic gene therapy platform.
2

The lead program, IKAR-001, targets geographic atrophy by co-expressing PEDF for neuroprotection and soluble CD46 for complement modulation.
3

Current single-pathway therapies for geographic atrophy show modest effects and inconsistent improvements in visual function.
4

Neuroprotection is critical for meaningful outcomes in geographic atrophy, as it addresses neurodegeneration directly.
5

Ikarovec's gene therapy aims to provide both anatomical and functional benefits, representing a next-generation treatment for retinal diseases.

1